Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Cardiovasc Ther. 2012 Oct;30(5):257-63. doi: 10.1111/j.1755-5922.2011.00280.x. Epub 2011 May 31.
The purpose of this review is to describe novel pharmacologic and nonpharmacologic preventive therapies, as well as new strategies to improve delivery of available therapies. Cardiovascular disease (CVD) is the leading cause of death worldwide, and prevention plays a critical role in curbing the global epidemic. Despite available treatment for tobacco addiction, platelet inhibition, blood pressure, and lipid lowering for reduction of atherosclerotic disease, significant gaps in treatment of total CVD remain. We review a range of new preventive treatment options, including drugs for tobacco cessation, platelet/thrombotic inhibition, lipid- and blood pressure-lowering; nonpharmacologic options such as left atrial appendage closure devices and caloric restriction; and strategies such as fixed-dose combination drugs, laboratory screening for drug tailoring, and community-based prevention programs. CVD preventive research continues to evolve and provide clinicians and patients with novel pharmacologic and nonpharmacologic therapies, including new preventive strategies.
本综述旨在描述新型的药物和非药物预防疗法,以及改善现有治疗方法应用的新策略。心血管疾病 (CVD) 是全球范围内的主要致死原因,预防对于遏制这一全球流行疾病至关重要。尽管有针对烟草成瘾、血小板抑制、血压和血脂降低以减少动脉粥样硬化疾病的治疗方法,但在 CVD 的整体治疗方面仍存在显著差距。我们回顾了一系列新的预防治疗选择,包括用于戒烟、血小板/血栓抑制、降脂和降压的药物;非药物选择,如左心耳封堵装置和热量限制;以及固定剂量联合药物、药物定制的实验室筛查和基于社区的预防计划等策略。CVD 预防研究不断发展,为临床医生和患者提供新型的药物和非药物治疗方法,包括新的预防策略。